CA2534317A1 - Benzimidazole acetonitriles - Google Patents

Benzimidazole acetonitriles Download PDF

Info

Publication number
CA2534317A1
CA2534317A1 CA002534317A CA2534317A CA2534317A1 CA 2534317 A1 CA2534317 A1 CA 2534317A1 CA 002534317 A CA002534317 A CA 002534317A CA 2534317 A CA2534317 A CA 2534317A CA 2534317 A1 CA2534317 A1 CA 2534317A1
Authority
CA
Canada
Prior art keywords
acetonitriles
benzimidazole
group
alkynyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002534317A
Other languages
English (en)
French (fr)
Inventor
Matthias Schwarz
Pascale Gaillard
Patrick Page
Jean-Pierre Gotteland
Russell J. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems Ars Holding N.V.
Matthias Schwarz
Pascale Gaillard
Patrick Page
Jean-Pierre Gotteland
Russell J. Thomas
Laboratoires Serono S.A.
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Matthias Schwarz, Pascale Gaillard, Patrick Page, Jean-Pierre Gotteland, Russell J. Thomas, Laboratoires Serono S.A., Merck Serono Sa filed Critical Applied Research Systems Ars Holding N.V.
Publication of CA2534317A1 publication Critical patent/CA2534317A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002534317A 2003-09-12 2004-09-10 Benzimidazole acetonitriles Abandoned CA2534317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03102741.0 2003-09-12
EP03102741 2003-09-12
PCT/EP2004/052137 WO2005026155A1 (en) 2003-09-12 2004-09-10 Benzimidazole acetonitriles

Publications (1)

Publication Number Publication Date
CA2534317A1 true CA2534317A1 (en) 2005-03-24

Family

ID=34306922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002534317A Abandoned CA2534317A1 (en) 2003-09-12 2004-09-10 Benzimidazole acetonitriles

Country Status (7)

Country Link
EP (1) EP1667995A1 (no)
JP (1) JP2007505085A (no)
AU (1) AU2004272306A1 (no)
CA (1) CA2534317A1 (no)
IL (1) IL174135A0 (no)
NO (1) NO20061614L (no)
WO (1) WO2005026155A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN113281309B (zh) * 2021-05-17 2022-03-01 深圳市罗湖区人民医院 一种毒死蜱、多菌灵、阿特拉津三合一检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
KR100860827B1 (ko) * 2000-09-06 2008-09-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 합성효소 키나아제 3의 억제제

Also Published As

Publication number Publication date
JP2007505085A (ja) 2007-03-08
AU2004272306A1 (en) 2005-03-24
EP1667995A1 (en) 2006-06-14
IL174135A0 (en) 2006-08-01
WO2005026155A1 (en) 2005-03-24
NO20061614L (no) 2006-04-10

Similar Documents

Publication Publication Date Title
NO20061614L (no) Benzimidazolacetonitriler
IL174250A0 (en) Use of benzothiazola derivatives for the preparation of medicament
CA2534312A1 (en) Sulfonamide derivatives for the treatment of diabetes
EP2287166A3 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DE602005013822D1 (de) Cycloalkylaminderivate
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
SE0102299D0 (sv) Compounds
EP2261216A3 (en) Pyrazoles as glucokinase activators
MY143249A (en) 4-substituted pyrrolidin-2-ones and their use
WO2006066747A8 (en) 4-aminopiperidine derivatives
TW200631580A (en) Substituted benzoquinolizine derivatives
EP1604989A8 (en) DPP-IV inhibitors
WO2007065808A3 (en) Neuropeptide-2 receptor-agonists
MX2009006444A (es) Metodo para producir derivado de c-glucosido e intermediario sintetico del mismo.
CA2534319A1 (en) Benzoxazole acetonitriles
WO2008035305A8 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
WO2005082404A3 (en) Glp-2 derivatives modified by lipophilic substituents
WO2008039087A8 (en) Indoline derivatives and uses thereof
RU2006113431A (ru) N-ацетилцистеинат 2-этил-6-метил-3-гидроксипиридина, обладающий антиоксидантными, гипогликемическими, гиполипидемическими и противошоковыми свойствами
PL1638959T3 (pl) 4-(Aminometylo)piperydynobenzamidy antagonistyczne względem 5HT4

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued